Organogenesis (NASDAQ:ORGO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Organogenesis (NASDAQ:ORGO) issued its earnings results on Thursday. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11, Zacks reports. The firm had revenue of $150.86 million for the quarter, compared to analysts’ expectations of $134.10 million. Organogenesis had a positive return on equity of 4.05% and a negative net margin of 1.30%. Organogenesis updated its FY 2025 guidance to EPS.

Organogenesis Stock Performance

Shares of ORGO stock traded up $1.74 on Friday, hitting $5.63. The stock had a trading volume of 32,983,255 shares, compared to its average volume of 722,316. The stock’s 50 day moving average is $4.43 and its 200-day moving average is $4.19. The firm has a market capitalization of $714.22 million, a price-to-earnings ratio of -46.92 and a beta of 1.68. Organogenesis has a 52-week low of $2.61 and a 52-week high of $6.71.

Institutional Trading of Organogenesis

Several large investors have recently modified their holdings of the business. Walleye Capital LLC acquired a new position in Organogenesis in the second quarter valued at approximately $45,000. Tower Research Capital LLC TRC raised its position in shares of Organogenesis by 590.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 23,655 shares of the company’s stock worth $87,000 after purchasing an additional 20,228 shares during the period. Strs Ohio bought a new stake in shares of Organogenesis in the 1st quarter worth approximately $105,000. Creative Planning boosted its position in Organogenesis by 84.5% during the 2nd quarter. Creative Planning now owns 35,392 shares of the company’s stock valued at $130,000 after purchasing an additional 16,205 shares during the period. Finally, Cetera Investment Advisers acquired a new position in Organogenesis during the 2nd quarter valued at approximately $222,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ORGO has been the topic of several research analyst reports. Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday. BTIG Research reaffirmed a “buy” rating and set a $7.00 price target on shares of Organogenesis in a research report on Friday, September 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Organogenesis in a research report on Wednesday, October 8th. Finally, Cantor Fitzgerald raised their target price on shares of Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.33.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.